Compare ASIC & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ASIC | LTGO |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2025 | 2026 |
| Metric | ASIC | LTGO |
|---|---|---|
| Price | $25.84 | $22.37 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $26.75 | N/A |
| AVG Volume (30 Days) | 50.9K | ★ 385.4K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.44 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $424,339,000.00 | N/A |
| Revenue This Year | $34.21 | N/A |
| Revenue Next Year | $34.65 | N/A |
| P/E Ratio | $21.43 | ★ N/A |
| Revenue Growth | ★ 23.41 | N/A |
| 52 Week Low | $16.35 | $17.22 |
| 52 Week High | $26.00 | $21.71 |
| Indicator | ASIC | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 62.76 | 85.35 |
| Support Level | $18.75 | $18.46 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.95 | 1.31 |
| MACD | 0.04 | 0.35 |
| Stochastic Oscillator | 94.36 | 96.70 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.